Teneligliptin

Teneligliptin

Teneligliptin

Chemical compound

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[1]

Quick Facts Clinical data, Trade names ...

Creation

It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.[2]

Licensing and use

Japan/Korea/India/Argentina

It is approved for use in Japan, Argentina, Korea and India.[3]

Pharmacology

Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.

Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.[4]

References

  1. [1]
    Kishimoto M (2013). "Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 6: 187–195. doi:10.2147/DMSO.S35682. PMC 3650886. PMID 23671395.
  2. [2]
    "TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy". Media & Investors. Daiichi Sankyo. 20 December 2013. Archived from the original on 24 November 2015.
  3. [3]
    Bronson J, Black A, Dhar TG, Ellsworth BA, Merritt JR (2013). "Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012". Annual Reports in Medicinal Chemistry. Vol. 48. pp. 523–524. doi:10.1016/b978-0-12-417150-3.00028-4. ISBN 978-0-12-417150-3.
  4. [4]
    Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T (May 2013). "A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site". Biochemical and Biophysical Research Communications. 434 (2): 191–196. doi:10.1016/j.bbrc.2013.03.010. PMID 23501107.
Share this article:

This article uses material from the Wikipedia article Teneligliptin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.